Literature DB >> 3486767

Compensatory maturational deceleration of growth or "catch-down growth" in patients with congenital adrenal hyperplasia after delayed initiation of therapy.

U Hunziker, R Largo, M Zachmann, A Prader.   

Abstract

The growth pattern is reported of 16 patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency in whom therapy was started after the age of 3 years. Treatment was initiated at a mean chronological age (CA) of 4.7 years (range 3.0-7.2) and at a mean bone age (BA) of 10.4 years (range 10.2-13.2). It consisted of hydrocortisone (mean dosage 26 mg/m2) or prednisone (8.7 mg/m2) in all, and of fluorohydrocortisone (0.05-0.1 mg daily) in five patients. At the last examination the mean duration of therapy was 5.2 years, the mean CA 10.0 years, and the mean BA 12.6 years. In 13 of the 16 patients a "catch-down growth" pattern was observed, which was characterised by a decrease in height (expressed as SDS) for CA, a deceleration of bone maturation and increase of height (SDS) for BA, and an improvement in predicted height (Bayley-Pinneau).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486767     DOI: 10.1007/BF00496033

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  12 in total

1.  The natural history of the Silver-Russell syndrome: a longitudinal study of thirty-nine cases.

Authors:  J M Tanner; H Lejarraga; N Cameron
Journal:  Pediatr Res       Date:  1975-08       Impact factor: 3.756

2.  The effect of therapy on mature height in congenital adrenal hyperplasia.

Authors:  R T Kirkland; B S Keenan; J H Holcombe; J L Kirkland; G W Clayton
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

3.  Experience with long-term therapy in congenital adrenal hyperplasia.

Authors:  C G Brook; M Zachmann; A Prader; G Mürset
Journal:  J Pediatr       Date:  1974-07       Impact factor: 4.406

4.  Maturational deceleration after treatment of congenital adrenal hyperplasia.

Authors:  A M Bongiovanni; T Moshang; J S Parks
Journal:  Helv Paediatr Acta       Date:  1973-05

5.  Linear growth rate, bone maturation and growth hormone secretion in prepubertal children with congenital adrenal hyperplasia.

Authors:  R Rappaport; E Bouthreuil; C Marti-Henneberg; A Basmaciogullari
Journal:  Acta Paediatr Scand       Date:  1973-09

6.  [Body measurements, growth velocity and bone age of healthy children up to 12 years of age (longitudinal growth study Zurich) (author's trnasl)].

Authors:  A Prader; H Budliger
Journal:  Helv Paediatr Acta       Date:  1977

7.  Acceptable linear growth in congenital adrenal hyperplasia.

Authors:  S C Duck
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

8.  Catch-up growth.

Authors:  A Prader
Journal:  Postgrad Med J       Date:  1978       Impact factor: 2.401

9.  Late-onset steroid 21-hydroxylase deficiency: a variant of classical congenital adrenal hyperplasia.

Authors:  B Kohn; L S Levine; M S Pollack; S Pang; F Lorenzen; D Levy; A J Lerner; G F Rondanini; B Dupont; M I New
Journal:  J Clin Endocrinol Metab       Date:  1982-11       Impact factor: 5.958

10.  Attenuated forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  P A Lee; Z Rosenwaks; M D Urban; C J Migeon; W D Bias
Journal:  J Clin Endocrinol Metab       Date:  1982-11       Impact factor: 5.958

View more
  2 in total

1.  Growth patterns after for virilising adrenocortical adenoma.

Authors:  B P Hauffa; C Roll; R Mühlenberg; W Havers
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

2.  Downward percentile crossing as an indicator of an adverse prenatal environment.

Authors:  Michelle Lampl; Francesca Gotsch; Juan Pedro Kusanovic; Jimmy Espinoza; Luis Gonçalves; Ricardo Gomez; Jyh Kae Nien; Edward A Frongillo; Roberto Romero
Journal:  Ann Hum Biol       Date:  2008 Sep-Oct       Impact factor: 1.533

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.